Ackerman did not name specific competitors by company during the interview. He did note that the competitive risk he thinks about most is small companies that could emerge quickly and claim to replicate Reveleer's AI-driven capabilities. He described two moats that he believes protect the business: proprietary access to data sets covering Medicare, Medicaid, diabetes, chronic heart disease, and related chronic conditions, which are difficult for startups to replicate; and an installed base of 70 health systems and insurers under contract, which he said represents a wide moat given how difficult it is to win business in those segments.
No competitor revenue figures or valuations were cited by Ackerman. Sisense was referenced by the host, not by Ackerman, as a separate Hercules borrower for context on loan terms; Sisense is not described as a Reveleer competitor and those figures are not attributed to Ackerman.